A study published in the Annals of the American Thoracic Society analyzed results from the ELEVATE-1 clinical trial testing the effects of rodatristat ethyl on daily activity in patients with pulmonary arterial hypertension (PAH).
PAH is a rare condition affecting the heart and lungs. It is characterized by abnormally high blood pressure (hypertension) in the pulmonary artery. Symptoms include shortness of breath during exercise and fainting spells. The symptoms tend to get worse over time and may include dizziness, edema of the ankles or legs, chest pain, and a racing pulse. Some cases of PAH are due to genetic changes in the BMPR2 gene. It can also occur secondary to underlying conditions such as connective tissue diseases, HIV infection, chronic hemolytic anemia, and congenital heart disease, or be induced by certain drugs and toxins.
A recent study looked at the effects of rodatristat ethyl on activity in patients with PAH.
Actigraphy, or wearable devices, were used as a functional outcome assessment capable of detecting changes in activity mediated by improvement in physiology in the ELEVATE-2 study.
ELEVATE-2 was a phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating rodatristat ethyl versus placebo in PAH. A total of 100 participants were analyzed and wore ActiGraph on their wrist.
Adjusted least-squares mean showed Peak 5-minute steps (-49 steps), moderate activity time (-17.3 minutes/day), and daily steps (-656) all decreased at week 24 after treatment with rodatristat ethyl compared to placebo. Peak 5-minute steps were weakly associated with changes in stroke volume index, 0.74.
To learn more about PAH and other rare heart conditions, visit https://checkrare.com/diseases/heart-diseases/